{"relation": [["", "BI 10773 Low (Drug Naive)", "BI 10773 High (Drug Naive)", "Placebo (Drug Naive)", "Sitagliptin 100mg (Drug Naive)", "BI 10773 Low (Pioglitazone)", "BI 10773 High (Pioglitazone)", "Placebo (Pioglitazone)", "BI 10773 Low (Metformin)", "BI 10773 High (Metformin)", "Placebo (Metformin)", "BI 10773 Low (Metformin+Sulfonylurea)", "BI 10773 High (Metformin+Sulfonylurea)", "Placebo (Metformin+Sulfonylurea)"], ["Description", "Patients rolled over from trial 1245.20 BI 10773 tablets once daily BI 10773: BI 10773 tablets once daily Placebo: Placebo matching Sitagliptin Placebo: Placebo matching BI 10773 high dose", "Patients rolled over from trial 1245.20 BI 10773 tablets once daily Placebo: Placebo matching Sitagliptin BI 10773: BI 10773 tablets once daily Placebo: Placebo matching BI 10773 low dose", "Patients rolled over from trial 1245.20 Placebo tablets matching BI 10773 / Sitagliptin once daily Placebo: Placebo matching BI 10773 low dose Placebo: Placebo matching Sitagliptin Placebo: Placebo matching BI 10773 high dose", "Patients rolled over from trial 1245.20 Sitagliptin once daily Placebo: Placebo matching BI 10773 high dose Placebo: Placebo matching BI 10773 low dose Sitagliptin 100mg: Sitagliptin once daily", "Patients rolled over from trial 1245.19 BI 10773 tablets once daily BI 10773: BI 10773 tablets once daily Placebo: Placebo matching BI 10773 high dose", "Patients rolled over from trial 1245.19 BI 10773 tablets once daily BI 10773: BI 10773 tablets once daily Placebo: Placebo matching BI 10773 low dose", "Patients rolled over from trial 1245.19 Placebo tablets matching BI 10773 once daily Placebo: Placebo matching BI 10773 low dose Placebo: Placebo matching BI 10773 high dose", "Patients rolled over from trial 1245.23 BI 10773 tablets once daily Placebo: Placebo matching BI 10773 high dose BI 10773: BI 10773 tablets once daily", "Patients rolled over from trial 1245.23 BI 10773 tablets once daily BI 10773: BI 10773 tablets once daily Placebo: Placebo matching BI 10773 low dose", "Patients rolled over from trial 1245.23 Placebo tablets matching BI 10773 once daily Placebo: Placebo matching BI 10773 low dose Placebo: Placebo matching BI 10773 high dose", "Patients rolled over from trial 1245.23 BI 10773 tablets once daily BI 10773: BI 10773 tablets once daily Placebo: Placebo matching BI 10773 high dose", "Patients rolled over from trial 1245.23 BI 10773 tablets once daily BI 10773: BI 10773 tablets once daily Placebo: Placebo matching BI 10773 low dose", "Patients rolled over from trial 1245.23 Placebo tablets matching BI 10773 Placebo: Placebo matching BI 10773 low dose Placebo: Placebo matching BI 10773 high dose"]], "pageTitle": "Safety and Efficacy of Empagliflozin (BI 10773) and Sitagliptin Versus Placebo Over 76 Weeks in Patients With Type 2 Diabetes - Study Results - ClinicalTrials.gov", "title": "", "url": "https://clinicaltrials.gov/ct2/show/results/NCT01289990?sect=X01256&view=results", "hasHeader": true, "headerPosition": "MIXED", "tableType": "RELATION", "tableNum": 308, "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042990112.92/warc/CC-MAIN-20150728002310-00028-ip-10-236-191-2.ec2.internal.warc.gz", "recordEndOffset": 855963187, "recordOffset": 855919482, "tableOrientation": "HORIZONTAL", "TableContextTimeStampAfterTable": "{7757=Patients rolled over from trial 1245.23, 5945=Patients rolled over from trial 1245.19, 3408=Patients rolled over from trial 1245.20}", "textBeforeTable": "Reporting Groups No text entered. Significant events and approaches for the overall study following participant enrollment, but prior to group assignment Pre-Assignment Details No text entered. Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations Recruitment Details \u00a0 Hide Participant Flow \u00a0 Participant Flow Drug: BI 10773 Drug: Placebo Drug: Sitagliptin 100mg Interventions: Diabetes Mellitus, Type 2 Condition: Allocation:\u00a0Non-Randomized; \u00a0 Endpoint\u00a0Classification:\u00a0Safety/Efficacy\u00a0Study; \u00a0 Intervention\u00a0Model:\u00a0Parallel\u00a0Assignment; \u00a0 Masking:\u00a0Double-Blind; \u00a0 Primary\u00a0Purpose:\u00a0Treatment Study Design: Interventional Study Type: Results First Received: May 16, 2014 \u00a0", "textAfterTable": "Participant Flow: \u00a0 Overall Study \u00a0 \u00a0 Empagliflozin 10 mg (Drug Naive) \u00a0 \u00a0 Empagliflozin 25 mg (Drug Naive) \u00a0 \u00a0 Placebo (Drug Naive) \u00a0 \u00a0 Sitagliptin 100mg (Drug Naive) \u00a0 \u00a0 Empagliflozin 10 mg (Pioglitazone) \u00a0 \u00a0 Empagliflozin 25 mg (Pioglitazone) \u00a0 \u00a0 Placebo (Pioglitazone) \u00a0 \u00a0 Empagliflozin 10 mg (Metformin) \u00a0 \u00a0 Empagliflozin 25 mg (Metformin) \u00a0 \u00a0 Placebo (Metformin) \u00a0 \u00a0 Empagliflozin 10 mg (Metformin+Sulfonylurea) \u00a0 \u00a0 Empagliflozin 25 mg (Metformin+Sulfonylurea) \u00a0 \u00a0 Placebo (Metformin+Sulfonylurea) \u00a0 STARTED \u00a0 \u00a0 224 \u00a0 \u00a0 224 \u00a0 \u00a0 228 \u00a0 \u00a0 223 \u00a0 \u00a0 165 \u00a0 \u00a0 168 \u00a0 \u00a0 166 \u00a0", "hasKeyColumn": false, "keyColumnIndex": -1, "headerRowIndex": 0}